



Cyp26a1 supports postnatal retinoic acid homeostasis and glucoregulatory control

Received for publication, January 13, 2023, and in revised form, March 13, 2023 Published, Papers in Press, April 1, 2023,
<https://doi.org/10.1016/j.jbc.2023.104669>

Hong Sik Yoo, Michael A. Cockrum, and Joseph L. Napoli*¹

From the Graduate Program in Metabolic Biology, Nutritional Sciences and Toxicology, UC-Berkeley, Berkeley, California, USA

Reviewed by members of the JBC Editorial Board. Edited by Qi-Qun Tang

Considerable evidence confirms the importance of Cyp26a1 to all-*trans*-retinoic acid (RA) homeostasis during embryogenesis. In contrast, despite its presence in postnatal liver as a potential major RA catabolizing enzyme and its acute sensitivity to induction by RA, some data suggested that Cyp26a1 contributes only marginally to endogenous RA homeostasis postnatally. We report reevaluation of a conditional *Cyp26a1* knockdown in the postnatal mouse. The current results show that *Cyp26a1* mRNA in WT mouse liver increases 16-fold upon refeeding after a fast, accompanied by an increased rate of RA elimination and a 41% decrease in the RA concentration. In contrast, *Cyp26a1* mRNA in the refeed homozygotic knockdown reached only 2% of its extent in WT during refeeding, accompanied by a slower rate of RA catabolism and no decrease in liver RA, relative to fasting. Refeed homozygous knockdown mice also had decreased Akt1 and 2 phosphorylation and pyruvate dehydrogenase kinase 4 (*Pdk4*) mRNA and increased glucokinase (*Gck*) mRNA, glycogen phosphorylase (Pygl) phosphorylation, and serum glucose, relative to WT. Fasted homozygous knockdown mice had increased glucagon/insulin relative to WT. These data indicate that Cyp26a1 participates prominently in moderating the postnatal liver concentration of endogenous RA and contributes essentially to glucoregulatory control.

All-*trans*-retinoic acid (RA), a metabolite of vitamin A (retinol), contributes to postnatal regulation of energy metabolism by preventing pre-adipocyte differentiation into mature white adipocytes, by stimulating lipolysis and by promoting fatty acid oxidation (1–6). RA dosing or reduction decreases or increases adiposity, respectively. RA also exerts glucoregulatory control by regulating endocrine pancreatic cell differentiation and by opposing insulin actions, including through inducing gluconeogenesis (7). Multiple metabolic reactions regulate RA tissue concentrations (8). These include retinol dehydrogenation into retinal, catalyzed by retinol dehydrogenases, reduction of retinal catalyzed by retinal reductases, dehydrogenation of retinal into RA, and retinol esterification to limit substrate available for RA biosynthesis. Insulin retards RA biosynthesis through expelling FoxO1 from the nucleus and diminishing the mRNA of retinol and retinal

dehydrogenases (9). This permits maximum insulin action during feeding, while maximizing RA actions during fasting.

Catabolism also contributes to RA homeostasis. Inhibiting catabolism with “conazoles” boosted RA potency and/or inhibited catabolism in cultured cells, providing early evidence that degradation tempers RA effects (10–12). Discovery of Cyp26a1 (aka P450RA1), as the founder of a unique family of cytochromes P450, identified enzymes specific to RA clearance (13–15). Several investigations have reported Cyp26a1 activities during mouse embryogenesis (16–19). *Cyp26a1* ablation causes embryonic lethality by mid to late gestation. Major defects include spina bifida and malformations of the kidneys, the urogenital tract, the hindgut, and abnormal neural differentiation. Atypical induction of *Cyp26a1* in mouse embryonic stem cells introduces defects in lineage differentiation (20). Ablation of the retinal dehydrogenase *Raldh2* rescues *Cyp26a1*-null mice substantially, indicating the importance of balancing RA concentrations by coordinating biosynthesis and catabolism (21). Also consistent with coordinate modulation of RA biosynthesis and catabolism, *Cyp26a1* and the retinol dehydrogenase *Rdh1* display inversely related mRNA expression in embryos (e7.5 to e18.5) and liver (e12.5 to P2M) (1). In postnatal rat liver, RA and vitamin A induce liver *Cyp26a1* expression potently and relatively rapidly, with a greater dynamic range than other potential P450s that catabolize RA (22). Even so, contributions of Cyp26a1 to postnatal RA homeostasis seem less certain. Postnatal ablation of *Cyp26a1* in Sertoli and germ cells revealed no involvement in RA function during spermatogenesis (23). A conditional, postnatal, whole-body *Cyp26a1* knockout did not alter RA serum and tissue concentrations or produce consistent adverse phenotypes (24). *Cyp26a1*-null mice, however, had disrupted retinoid-induced myeloid hematopoiesis. These data fostered the conclusion that Cyp26a1 has no significant influence in regulating endogenous RA signaling. *Cyp26a1* knockout, however, decreased the elimination rate of a toxic RA dose (10 mg/kg) in mouse plasma by 6-fold, prompting the conclusion that Cyp26a1 contributes significantly only to clearing exogenous RA overdose.

We have reported that glucagon and cortisol secreted during fasting decrease *CYP26A1* mRNA, whereas refeeding increases its mRNA (25). The decrease in *CYP26A1* mRNA occurred *via* the glucocorticoid receptor binding to the RAR α coactivation complex, hampering its transcriptional activity.

* For correspondence: Joseph L. Napoli, jna@berkeley.edu.

Cyp26a1 affects retinoic acid and insulin signaling

Inhibition of RA catabolism during fasting, a phase of optimum RA biosynthesis, helps maintain high RA concentrations. By accelerating RA catabolism, the increase in Cyp26a1 during refeeding complements insulin action in arresting RA biosynthesis. These data suggest an essential contribution of Cyp26a1 to RA's regulation of postnatal energy balance and provide additional evidence that RA and energy balance relate closely to each other. The present work aimed to extend insight into the contribution of liver Cyp26a1, because human, rat, and mouse livers express *CYP26A1/Cyp26a1* intensely, but express *CYP26B1/Cyp26b1* and *CYP26C1/Cyp26c1* weakly (26–29). Here, we further examine two issues: the contribution(s) of Cyp26a1 to regulating liver RA concentrations and the physiological importance of Cyp26a1. We report that *Cyp26a1* contributes substantially to moderating the endogenous liver RA concentration in postnatal mice, and its ablation disrupts glucoregulatory control.

Results

The current experiments relied on a conditional knockdown (KD) of *Cyp26a1* and a purified diet that contained sufficient but not copious amounts of vitamin A. *Cyp26a1*-floxed

tamoxifen (tam)-inducible Cre mice were administered tam at 4-weeks-old for five consecutive days (Fig. 1A). Glucose tolerance (GTT) and insulin tolerance tests (ITT) were done at 7- and 8-weeks-old, respectively, on the same mice. Serum and liver tissues were harvested at 9-weeks-old following a 16 h fast or upon 6 h refeeding after a 16 h fast.

Cyp26a1 mRNA in WT mouse liver responded with a 16-fold increase to 6 h refeeding after an overnight fast (Fig. 1B). Tam-induced Cre-driven KD decreased *Cyp26a1* mRNA in fasted heterozygous and homozygous mice to 19% and 1.6% of WT, respectively. After refeeding, *Cyp26a1* mRNA increased to only ~21 and 2% of WT in heterozygous and homozygous KD mice, respectively. Consistent with previous observations, refeeding prompted a 41% decrease in WT liver RA (9, 25) (Fig. 1C). Increased liver RA during fasting and decreased liver RA during refeeding serves its function as an anti-insulin autacoid (7). In contrast to WT, neither the heterozygous nor the homozygous KD mouse liver decreased RA after refeeding. *Cyp26a1* KD also decreased the rate of RA elimination by liver microsomes (Fig. 1D). WT liver microsomes eliminated RA at half-lives of 89 and 65 min during fasting and refeeding, respectively. The $t_{1/2}$ elimination rates increased to 141 and 110 min in homozygous fasted and refeed




Figure 1. Cyp26a1 knockdown prevents the decrease in liver RA in response to feeding. A, protocol for creating and evaluating all strains of mice. All genotypes were treated identically. B, *Cyp26a1* mRNA in livers (n = 5–15). C, quantification of liver RA by LC/MS/MS (n = 5–15). D, microsomal RA catabolism, elimination $t_{1/2}$ were determined by quantifying by LC/MS/MS the ln % remaining of 50 pmol RA with the time of microsomal incubation. *Cyp26a1* WT, +/+; WT/Cre+ heterozygous, f/+; *Cyp26a1* homozygous floxed and Cre+, f/f. Red open circles: fasted 16 h; black filled squares: refeed 6 h following fasting 16 h. RA, retinoic acid. ** $p < 0.01$; *** $p < 0.001$.

KD mice, respectively. Neither retinyl esters nor retinol in liver varied by fasting *versus* refeeding or with genotypes (Fig. S1, A and B). We also confirmed that serum RA does not reflect liver RA, as published previously (Fig. S1C) (30).

No apparent signs of gross liver damage presented in H&E-stained sections of any genotype, such as necrosis, steatosis, or fibrosis (Fig. S2). Glycogen deposits appeared in refeed groups but did not differ by genotype (Fig. S3). Inflammation lesions occurred in two of four homozygous KD mice examined (Fig. S4, A and B). Although they were minimal to mild, the lesions accompanied yellow-green deposits of the iron-containing protein hemosiderin, distinguishable from spontaneous inflammation foci observed in WT liver sections (Fig. S4, C–E).

GTTs did not differ among genotypes (Fig. 2A). Upon an insulin challenge (ITT), glucose levels in each genotype decreased at similar rates (Fig. 2B). After 60 min, however, serum glucose levels began to diverge, eventually reaching a statistically significant increase in homozygous KD relative to WT. Serum glucose increased 46 mg/dl more in refeed homozygous KD mice than WT (Fig. 2C). We hypothesized that the elevated glucose resulted from an increase in hepatic glucose production, indicating insulin resistance in liver. Western blots of Akt serine/threonine kinase 1 and 2 (Akt1 and Akt2) *versus* phosphorylated Akt1 and Akt2 showed that fasting increased phosphorylation of both Akt1 and 2 in WT mice, as expected, by >3-fold and 4.5-fold, respectively




Figure 2. *Cyp26a1* deficiency attenuates insulin signaling. A, glucose tolerance tests (n = 10–30 mice). B, insulin tolerance tests (n = 10–30 mice). C, serum glucose at 9 weeks old after 16 h fasting or 6 h refeeding after a 16 h fast (n = 6–15 mice). D, Western blots of pAkt1/Akt1 and pAkt2/Akt2 (n = 4 mice). E, hepatic triacylglycerol (TAG) was determined by a colorimetric ELISA (n = 6–14 mice). F, ratio of serum glucagon/insulin (mole-to-mole, n = 5–15 mice). G, quantification of corticosterone in liver by LC/MS/MS (n = 5–15 mice). Fasted, red circles; refeed black squares. *p<0.05, **p<0.01, *** p<0.001.

Cyp26a1 affects retinoic acid and insulin signaling

(Fig. 2D). The degrees of Akt1 and Akt2 phosphorylation between fasted and re-fed homozygous KD mice were blunted (~2-fold each) and did not reach statistical significance ($p \sim 0.06$). Liver triacylglycerol (TAG) did not differ significantly in WT fasting *versus* re-fed mice. TAG in livers of re-fed KD mice was significantly lower than in fasted mice, with homozygous KD mice attaining only 61% of the level in fasted WT mice (Fig. 2E). The glucagon/insulin ratio in fasted homozygous KD increased ~2.3-fold more than WT (Fig. 2F), driven by the glucagon increase in the homozygote KD during fasting (Fig. S5). Corticosterone increased >6-fold during fasting in WT mice but only ~2-fold in KD mice (Fig. 2G).

Phosphorylated Akt phosphorylates the FoxO1 transcription factor, which causes its nuclear export and proteolysis, resulting in decreased expression of phosphoenolpyruvate carboxykinase (*Pck1*) and glucose-6 phosphatase (*G6pc*) (31). *Pck1* expression increased during fasting, as expected, but did not differ among genotypes, during fasting or after refeeding (Fig. 3A). *G6pc* expression increased ~1.5-fold during fasting in homozygous KD relative to WT but did not attain statistical significance ($p \sim 0.08$). (Fig. 3B). *Gys2* mRNA, which encodes the rate-limiting enzyme of glycogen synthesis, did not change with genotype during fasting or refeeding (Fig. S6). *Gck* mRNA increased in all genotypes with refeeding but extended 1.4-fold




Figure 3. Effects of Cyp26a1 knockdown on gluco-regulation. A, *Pck1* mRNA. B, *G6pc* mRNA. C, *Gck* mRNA. D, *Pdk4* mRNA. E, *Pygl* mRNA. F, Western blots of phosphorylated Pygl (p-Ser15). All $n = 5$ to 15 mice, except Pygl Western blot, where $n = 4$ mice each genotype, each dietary condition. Red circles, fasted 16 h; black squares, 6 h re-fed after 16 h fasted. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

higher in refed homozygous KD mice relative to WT (Fig. 3C), consistent with the increased serum glucose (Fig. 2C). Fasting induces *Pdk4* expression, which inhibits the pyruvate dehydrogenase complex and increases pyruvate for gluconeogenesis (32). Fasting increased *Pdk4* mRNA, but no differences occurred by genotype (Fig. 3D). In contrast, *Pdk4* mRNA in refed homozygous KD mice reached only 46% of the level in WT mice. This suggests a shift during refed homozygous KD mice from sparing pyruvate to generating acetyl-CoA. Glycogen phosphorylase (*Pygl*) mRNA, which encodes the rate-limiting enzyme of liver glycogenolysis, also did not change with fasting *versus* refeeding or with genotype (Fig. 3E). Insulin induced dephosphorylation and inactivation of phospho-Pygl in WT, but not in the homozygous KD mice (Fig. 3F).

Discussion

This work addresses two issues primarily: actions of Cyp26a1 in regulating the liver RA concentration, and because Cyp26a1 activity links critically to the physiological functions of RA, we determined contributions of Cyp26a1 to glucoregulatory control. Decreases in *Cyp26a1* mRNA in heterozygous and homozygous KD mice accompanied 56% increases in liver RA during refeeding relative to WT mice, consistent with a major contribution of liver Cyp26a1 to regulating RA. Changes in the RA elimination $t_{1/2}$ provide additional insight. These values show that in addition to Cyp26a1 exerting a major impact during refeeding, it also does so during fasting. For example, in WT mice, the RA elimination $t_{1/2}$ increased by 25 min during fasting relative to refeeding. In the homozygous KD, this value increased by 40 min during fasting relative to refeeding. Moreover, fasted homozygous KD mice had an extended RA elimination $t_{1/2}$ of 52 min relative to fasted WT mice. Therefore, Cyp26a1 contributes to the catabolism of endogenous RA in liver during both fasting and refeeding. Lack of an increase in liver RA concentrations during fasting in KD *versus* WT mice likely indicates regulatory mechanisms other than Cyp26a1 activity. RA homeostasis reflects actions of cellular retinol-binding proteins, multiple retinol and retinal dehydrogenases, retinal reductases, retinol esterification enzymes, and retinyl ester hydrolases, besides catabolic enzymes (33). Another tier of regulation involves positive feedback by RA to induce lecithin:retinol acyltransferase to limit the retinol concentration. Overall, these data indicate a complex process during fasting, which involves more than *Cyp26a1* expression and activity, while affirming the contribution of liver Cyp26a1 to regulating RA.

Multiple metabolic intermediates and hormones regulate hepatic glucose production (34–36). The glucagon/insulin ratio exerts enormous influence, as do corticoids. An increase in the glucagon/insulin ratio in the fasted KD mice reflects insulin resistance and would increase gluconeogenesis, hepatic glucose secretion, and/or glycogenolysis (37). Although RA regulates *Pck1* and *G6pc* transcriptionally (38, 39), RA did not increase measurably during fasting in the homozygous KD mouse, accounting for their lack of increase. Corticosterone,

another inducer of *G6pc*, did not decrease significantly during fasting in KD, perhaps accounting for the lack of a significant difference in *G6pc* (40).

Most metabolic differences between WT and homozygous KD mice occurred during refeeding, consistent with the increased RA concentration in KD mice. The increase during refeeding of serum glucose suggests insulin resistance, as manifested by decreased Akt phosphorylation and the increase in serum glucose. The serum glucose increase, along with the increase in RA, likely induced the increase in liver *Gck* mRNA, a gene transcriptionally regulated by RA (41). The decrease in *Pdk4* would allow an increase in activity of the pyruvate dehydrogenase complex, thereby decreasing pyruvate and gluconeogenesis and providing additional acetyl-CoA for entry into the TCA cycle. The relative TAG decreases in the liver of fed KD mice indicate insulin resistance, the increase in the glucagon/insulin ratio, and/or the increase in RA. Apparently, the overall increase in blood glucose and the decrease in TAG represents the sum of counterbalancing controls. The increase in all genotypes in *Pck1* mRNA reveals synergistic induction by RA and glucocorticoids (42). A lack of an increase in *Pck1* during fasting in the KD mice relative to WT, when corticoids and RA attain maximum levels, perhaps indicates maximum induction had occurred. No data indicate that RA regulates *Gys2* and *Pygl* mRNA, accounting for the lack of transcriptional responses in these genes. *Pygl*, however, undergoes insulin-induced dephosphorylation and inactivation after feeding and glucagon-induced phosphorylation and activation during fasting (43). The lack of a decrease in *Pygl* phosphorylation in the refed KD mouse reflects the impact of the increased glucagon/insulin ratio on the liver and would contribute to the increased serum glucose.

Zhong *et al.* (24) reported a decrease in erythropoiesis in KD mice, which might underlie the liver hemosiderin deposits observed in this report. Liver hemosiderin results from excess iron deposited from blood iron or from ferritin breakdown (44). The Zhong report concluded Cyp26a1 has minor effects on postnatal RA homeostasis and contributes only to catabolism of exogenous RA. We have generated data to the contrary, but our experimental protocol contrasts in several essential properties with those in the Zhong report. The latter fed a commercial grain-based chow diet with copious vitamin A (20 IU vitamin A with 1.5 ppm β -carotene/g diet, followed by 30 IU vitamin A/g diet). Chow diets with copious vitamin A have improved or rescued phenotypes of three retinoid-related gene KOs, *Rdh1*, *Rbp4*, and *Crbp2* (1, 45, 46). The purified diet used in the current study contained 4 IU vitamin A/g, as recommended by the National Research Council for rodents (47, 48). Vitamin A exerts hormesis, that is, it wields concentration-dependent effects. In addition, grain-based diets contain multiple cereal grains, which vary seasonally, and harbor mycotoxins, heavy metals, and other pollutants, absent in purified diets (49). Grain-based diets also contain phytoestrogens that function as estrogen receptor modifiers. Crosstalk between RA and estrogen occurs and modifies the actions of each (5, 6). Purified diets, as used here, do not rely on grain for carbohydrates, but on cornstarch, dextrin, and sucrose. Finally,

Cyp26a1 affects retinoic acid and insulin signaling

glucoregulatory mechanisms were not evaluated in the Zhong report, which assessed ad lib–fed mice. Ad lib–fed mice occur individually in a dietary status between fasted and fed and would have RA levels varying individually between the two energy states. The major variables of evaluating ad lib–fed mice, feeding diets copious in vitamin A, and not assessing glucoregulatory control amply account for the differences in conclusions.

The data herein affirm a contribution of Cyp26a1 to RA homeostasis postnatally and further show that Cyp26a1 contributes to glucoregulatory control. Inhibition of RA metabolism could provide an alternative to RA dosing. RA metabolism–blocking agents (aka RAMBA), that is, inhibitors of Cyp26 isomers, have been evaluated for therapeutic use to increase endogenous RA concentrations (50, 51). This approach represents an attempt to increase tissue RA, while avoiding the toxic effects of RA dosing, the short half-life of dosed RA, and autoinduction of RA degradation. RAMBA have been used for treating dermatological diseases, such as acne, psoriasis, and ichthyosis, and have undergone clinical trials for treating prostate and breast cancer, with limited effects. RAMBA developed so far do not seem selective for inhibiting RA catabolism, which also limits their use. The current report suggests another cautionary note for RAMBA use: potential disruption of glucoregulatory control.

Experimental procedures

Mice

Inducible *Cyp26a1*-deficient male mice were generated by crossing the tamoxifen-inducible Cre line, B6.129-*Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/J* (strain# 008463), purchased from The Jackson Laboratory, with *Cyp26a1*-floxed mice donated by Dr Martin Petkovich (16). Three experimental groups (*Cyp26a1* +/+, *Cyp26a1* f/+, *Cyp26a1* f/f) were produced by F1 x F1 crossing (*Cyp26a1* f/+ with tam Cre+/-). All mice were administered tam once daily by i.p. injection (75 mg/kg) at 4-weeks-old for five consecutive days, as reported previously (16, 23, 24). No mice succumbed to tam dosing. Mice were fed a purified AIN93G diet (Research Diets, D10012G) containing 4 IU retinyl acetate/g and 7% fat. Serum and liver samples were collected from 9-weeks-old mice fasted 16 h and compared to those refed 6 h after a 16 h fast, after anesthesia in an isoflurane chamber, followed by cervical dislocation. Blood samples, drawn from the vena cava, were allowed to clot on ice and centrifuged 30 min at 12,000g and 4 °C. Sera and livers were snap-frozen in liquid nitrogen and stored at –80 °C until assayed. Animal experimental protocols were approved by the University of California Berkeley Animal Care and Use Committee.

GTTs and ITTs

GTTs were done at 7-weeks-old. ITTs were done at 8-weeks-old on the same mice (Fig. 1A). Mice were fasted 16 h (5 PM–9 AM) before the GTT and 4 h in the morning before the ITT and housed in individual cages without food, but with free access to water. Either glucose (2 g/kg body weight) or

insulin (0.5 IU/kg body weight) was injected I.P. Blood glucose from tail tips was measured using an Ascensia CONTOUR NEXT glucometer.

H&E staining of liver sections

Segments ~1.5 cm long and 3 mm thick were cut from the middle of the left lobe and fixed in 10% neutral buffered formalin (Sigma HT501128) for 3 days. Formalin-fixed, paraffin-embedded liver segments were cut into 8- μ m sections. Deparaffinized sections were stained with H&E. Tissue sections were imaged using a Zeiss Axio Imager M1 microscope equipped with QImaging 5MPix MicroPublisher.

Retinoid quantification

Retinyl esters and retinol were quantified by LC/UV (52). RA was quantified by LC/MS/MS, following a published method with the modification that liver was homogenized in methanol and centrifuged 5 min at 1200g to remove precipitates (25).

Liver microsomal assays

Liver samples (~100 mg) were homogenized in buffer (10 mM Tris–HCl, 250 mM sucrose, pH 7.4) using a glass pestle tissue grinder on ice. The homogenate was centrifuged 10 min at 10,000g and 4 °C. The supernatant was ultracentrifuged 1 h at 100,000g and 4 °C. The microsomal pellet was resuspended in assay buffer (150 mM KCl, 5 mM MgCl₂, 20 mM Tris–HCl, pH 7.4). RA catabolism was assessed at 37 °C. The 0.5 ml incubation mixture contained the assay buffer, 50 pmol RA, an NADPH regenerating system (5 units of glucose-6-phosphate dehydrogenase, 500 nmol NADP⁺, 500 nmol glucose 6-phosphate), and 50 μ g microsomal protein. The reaction was terminated by adding 2 ml methanol.

Western blots

Proteins in liver samples were extracted with 1 ml RIPA buffer (Thermo Fisher Scientific, 89901), which included protease and phosphatase inhibitors (Thermo Fisher Scientific, A32961). The Bradford assay determined total protein concentrations. Thirty micrograms of protein were mixed 1:1 with Laemmli sample buffer (Bio-Rad, 1610737), including 5% β -mercaptoethanol, heated 5 min at 95 °C, and cooled on ice. Protein samples were separated by 12% SDS-PAGE (Bio-Rad, 4561044), transferred onto nitrocellulose membranes (Bio-Rad, 1620115), which were blocked in Intercept (TBS) blocking buffer (LI-COR, 927-60001), and immunoblotted overnight at 4 °C with antibodies against Akt1 (Cell Signaling, D9R8K), phospho(S473)-Akt1 (Cell Signaling, D7F10), Akt2 (Cell Signaling, 5B5), phospho(S474)-Akt2 (Cell Signaling, D3H2), phospho-(S15)-Pygl (Thermo Fisher Scientific, PA5-114628), and β -actin (Abcam, ab8226). Primary antibodies were diluted 1:2000. Near-infrared fluorescent dye-conjugated secondary antibodies were as follows: anti-rabbit (LI-COR, 926-32211) and anti-mouse (LI-COR, 926-68070) at 1:5000. Immunoblots were developed with a LICOR Odyssey Imaging System. Western blot band density was quantified by integrating areas under curves using ImageJ 1.53. Antibodies for

phosphor-Akt1 and Akt2 were stripped by shake-incubating in Restore PLUS Western blot stripping buffer (Thermo Fisher Scientific, 46430) at 37 °C for 10 min, followed by reblock and immunoblotting with the Akt1 and 2 antibodies. Signals were normalized to actin. For p-Pygl, actin-normalized signals were then normalized to the average of WT fasted set as 1. Data are provided in [Table S1](#).

Gene expression assays

Total RNA was isolated using TRI Reagent (Sigma, T9424), quantified using a ThermoScientific NanoDrop One, and reverse-transcribed using iScript cDNA Synthesis Kit (Bio-Rad, 1708891). Quantitative PCR was performed with a Bio-Rad CFX Connect Real-Time Detection System using PrimeTime Gene Expression Master Mix (Integrated DNA Technologies (1055772)). Gene expression was analyzed by the $\Delta\Delta$ -Ct method, normalized to *Gusb*, and expressed as fold change relative to controls. Primers are listed in [Table S2](#).

Biochemical assays

Insulin, glucagon, glycogen, and TAG were quantified using Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, 90080), Mouse Glucagon ELISA Kit (Crystal Chem, 81518), Glycogen Assay Kit (BioVision, K646-100), and Triglyceride Quantification Colorimetric/Fluorometric Kit (Sigma, MAK266), following manufacturers' instructions.

Corticosterone quantification

A mixture of 1.5 ml methanol and 40 μ l corticosterone-d8 internal standard (Santa Cruz Biotechnology, sc-396031) was added into 2 ml Eppendorf tubes, each containing a metal bead. Liver (~50 mg) samples were added and homogenized using a Qiagen TissueLyser II at 30/s for 30 s. Homogenates were centrifuged 10 min at 12,000g and at 4 °C. Supernatants were transferred to round bottom glass tubes and methanol was evaporated under gentle N₂ streams. Precipitates were resuspended in 2 ml of 0.2 M acetate buffer (pH 5.0) and vortexed 20 s. Ten milliliters of methyl *t*-butyl ether were added. Tubes were vortexed 20 s and centrifuged at 3 min 2000g. The upper organic phases were transferred to a new round bottom glass tube and evaporated under gentle N₂ streams. Precipitates were resuspended in 40 μ l methanol. One microliter was injected into HPLC-APCI/MS/MS.

Corticosterone was resolved *via* reverse-phase chromatography with an Agilent 1290 system equipped with a binary pump, column compartment, and autosampler. The column compartment was maintained at 40 °C. Samples were kept in the autosampler at 10 °C. Separation was achieved with an analytical Ascentis Express RP-Amide column (100 \times 2.1 mm, 2.7 μ m, Sigma Aldrich, 53913-U) at a flow rate of 0.4 ml/min. Mobile phases were (A) 0.1% formic acid in water; (B) 0.1% formic acid in methanol. The following gradient was applied over 25 min: 0 to 2 min, 40% B; 2 to 15 min, 40 to 95% B; 15 to 20 min, holding at 95% B; 20 to 23.5 min, 95 to 40% B; 23.5 to 25 min, back to 40% B and reequilibrating for 1.5 min.

Analytes were detected with a Sciex API-4000 triple-quadrupole mass spectrometer in positive atmospheric pressure chemical ionization mode. Analyst version 1.6 software controlled the instrument, which was operated in the multiple reaction monitoring mode. Mass transitions to produce optimum sensitivity were determined by injecting 1 pmol standards (corticosterone: m/z 347.4 \rightarrow 329.5, corticosterone-d8: m/z 355.7 \rightarrow 337.7). Optimized MS variables were as follows: curtain gas, 10 psig; collision gas, 7 psig; ion source gas 1, 70 psig; nebulizer current, 3 μ A; source temperature, 350 °C; declustering potential, 55 V; entrance potential, 10 V; collision exit potential, 5 V. Optimized collision energy value was 25 eV.

Data presentation and statistics

Data are means \pm SD. Two-tailed unpaired nonparametric Mann-Whitney tests compared data between two groups. False discovery rate (1%)-adjusted *p*-values were reported for correcting multiple comparisons. Significance values are: **p* < 0.05, ***p* < 0.01, and ****p* < 0.001. Western blot band density was measured by integrating areas under curves using ImageJ 1.53. Statistical testing was done using GraphPad Prism 9.5.0.

Data availability

All data are contained within the manuscript.

Supporting information—This article contains supporting information.

Acknowledgments—We thank Dr Martin Petkovich, Department of Biomedical and Molecular Sciences, Cancer Research Institute, Queen's University, Kingston, ON, Canada for providing *Cyp26a1* floxed mice and Dr Denise Schichnes, College of Natural Resources Biological Imaging Facility, UC-Berkeley, for help with histology and imaging.

Author contributions—H. S. Y. and J. L. N. methodology; H. S. Y. and M. A. C. investigation; H. S. Y. and J. L. N. writing—original draft.

Funding and additional information—This work was funded by NIH grants DK112754 (J. L. N.) and DK107773 (J. L. N.). The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Abbreviations—The abbreviations used are: Akt, Akt serine/threonine kinase; Cyp, cytochrome P-450; G6pc, glucose-6-phosphatase; Gck, glucokinase; GTT, glucose tolerance test; ITT, insulin tolerance test; KD, knockdown; Pygl, glycogen phosphorylase liver isoform; Pck1, phosphoenolpyruvate kinase; Pdk4, pyruvate dehydrogenase kinase 4; RA, retinoic acid; TAG, triacylglycerol.

Cyp26a1 affects retinoic acid and insulin signaling

References

- Zhang, M., Hu, P., Krois, C. R., Kane, M. A., and Napoli, J. L. (2007) Altered vitamin A homeostasis and increased size and adiposity in the *rdh1*-null mouse. *FASEB J.* **21**, 2886–2896
- Noy, N. (2013) The one-two punch: retinoic acid suppresses obesity both by promoting energy expenditure and by inhibiting adipogenesis. *Adipocyte* **2**, 184–187
- Li, Y., Wong, K., Walsh, K., Gao, B., and Zang, M. (2013) Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. *J. Biol. Chem.* **288**, 10490–10504
- Cione, E., Caroleo, M. C., Cannataro, R., Perri, M., Pingitore, A., and Genchi, G. (2016) Vitamin A and diabetes: new insight for drug discovery. *Mini Rev. Med. Chem.* **16**, 738–742
- Yang, D., Vuckovic, M. G., Smullin, C. P., Kim, M., Lo, C. P.-S., Devericks, E., et al. (2018) Modest decreases in endogenous all-trans-retinoic acid produced by a mouse *Rdh10* heterozygote provoke major abnormalities in adipogenesis and lipid metabolism. *Diabetes* **67**, 662–673
- Zhao, Y., Vuckovic, M., Yoo, H. S., Fox, N., Rodriguez, A., McKessy, K., et al. (2021) Retinoic acid exerts sexually dimorphic effects on muscle energy metabolism and function. *J. Biol. Chem.* **297**, 101101
- Napoli, J. L. (2022) Retinoic acid: sexually dimorphic, anti-insulin and concentration-dependent effects on energy. *Nutrients* **14**, 1553
- Napoli, J. L. (2012) Physiological insights into all-trans-retinoic acid biosynthesis. *Biochim. Biophys. Acta* **1821**, 152–167
- Obrochta, K. M., Krois, C. R., Campos, B., and Napoli, J. L. (2015) Insulin regulates retinol dehydrogenase expression and all-trans-retinoic acid biosynthesis through FoxO1. *J. Biol. Chem.* **290**, 7259–7268
- Williams, J. B., and Napoli, J. L. (1985) Metabolism of retinoic acid and retinol during differentiation of F9 embryonal carcinoma cells. *Proc. Natl. Acad. Sci. U. S. A.* **82**, 4658–4662
- Napoli, J. L. (1986) Retinol metabolism in LLC-PK1 Cells. Characterization of retinoic acid synthesis by an established mammalian cell line. *J. Biol. Chem.* **261**, 13592–13597
- Williams, J. B., and Napoli, J. L. (1987) Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells. *Biochem. Pharmacol.* **36**, 1386–1388
- Fujii, H., Sato, T., Kaneko, S., Gotoh, O., Fujii-Kuriyama, Y., Osawa, K., et al. (1997) Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. *EMBO J.* **16**, 4163–4173
- Ray, W. J., Bain, G., Yao, M., and Gottlieb, D. I. (1997) CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. *J. Biol. Chem.* **272**, 18702–18708
- White, J. A., Beckett-Jones, B., Guo, Y. D., Dilworth, F. J., Bonasoro, J., Jones, G., et al. (1997) cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. *J. Biol. Chem.* **272**, 18538–18541
- Abu-Abed, S., Dollé, P., Metzger, D., Beckett, B., Chambon, P., and Petkovich, M. (2001) The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. *Genes Dev.* **15**, 226–240
- Sakai, Y., Meno, C., Fujii, H., Nishino, J., Shiratori, H., Saijoh, Y., et al. (2001) The retinoic acid-inactivating enzyme CYP26 is essential for establishing an uneven distribution of retinoic acid along the anterior-posterior axis within the mouse embryo. *Genes Dev.* **15**, 213–225
- McCaffery, P. J., Adams, J., Maden, M., and Rosa-Molinar, E. (2003) Too much of a good thing: retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. *Eur. J. Neurosci.* **18**, 457–472
- Pennimpede, T., Cameron, D. A., MacLean, G. A., Li, H., Abu-Abed, S., and Petkovich, M. (2010) The role of CYP26 enzymes in defining appropriate retinoic acid exposure during embryogenesis. *Birth Defects Res. A. Clin. Mol. Teratol.* **88**, 883–894
- Jin, L., Chang, C., Pawlik, K. M., Datta, A., Johnson, L. M., Vu, T., et al. (2018) Serine threonine kinase receptor-associated protein deficiency impairs mouse embryonic stem cells lineage commitment through CYP26a1-mediated retinoic acid homeostasis. *Stem Cells* **36**, 1368–1379
- Niederreither, K., Abu-Abed, S., Schuhbauer, B., Petkovich, M., Chambon, P., and Dollé, P. (2002) Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development. *Nat. Genet.* **31**, 84–88
- Yamamoto, Y., Zolfaghari, R., and Ross, A. C. (2000) Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats. *FASEB J.* **14**, 2119–2127
- Hogarth, C. A., Evans, E., Onken, J., Kent, T., Mitchell, D., Petkovich, M., et al. (2015) CYP26 enzymes are necessary within the postnatal seminiferous epithelium for normal murine spermatogenesis. *Biol. Reprod.* **93**, 19
- Zhong, G., Hogarth, C., Snyder, J. M., Palau, L., Topping, T., Huang, W., et al. (2019) The retinoic acid hydroxylase Cyp26a1 has minor effects on postnatal vitamin A homeostasis, but is required for exogenous atRA clearance. *J. Biol. Chem.* **294**, 11166–11179
- Yoo, H. S., Rodriguez, A., You, D., Lee, R. A., Cockrum, M. A., Grimes, J. A., et al. (2022) The glucocorticoid receptor represses, whereas C/EBP β can enhance or repress CYP26A1 transcription. *iScience* **25**, 104564
- Xi, J., and Yang, Z. (2008) Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell. *Gene Expr. Patterns* **8**, 438–442
- Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., et al. (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol. Cell Proteomics* **13**, 397–406
- Yu, Y., Zhao, C., Su, Z., Wang, C., Fuscoe, J. C., Tong, W., et al. (2014) Comprehensive RNA-Seq transcriptomic profiling across 11 organs, 4 ages, and 2 sexes of Fischer 344 rats. *Sci. Data* **1**, 140013
- Yue, F., Cheng, Y., Breschi, A., Vierstra, J., Wu, W., Ryba, T., et al. (2014) A comparative encyclopedia of DNA elements in the mouse genome. *Nature* **515**, 355–364
- Obrochta, K. M., Kane, M. A., and Napoli, J. L. (2014) Effects of diet and strain on mouse serum and tissue retinoid concentrations. *PLoS One* **9**, e99435
- Thiel, G., Guethlein, L. A., and Rössler, O. G. (2021) Insulin-responsive transcription factors. *Biomolecules* **11**, 1886
- Sugden, M. C., and Holness, M. J. (2003) Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. *Am. J. Physiol. Endocrinol. Metab.* **284**, E855–862
- O'Connor, C., Varshosaz, P., and Moise, A. R. (2022) Mechanisms of feedback regulation of vitamin A metabolism. *Nutrients* **14**, 1312
- Rui, L. (2014) Energy metabolism in the liver. *Compr. Physiol.* **4**, 177–197
- Petersen, M. C., Vatner, D. F., and Shulman, G. I. (2017) Regulation of hepatic glucose metabolism in health and disease. *Nat. Rev. Endocrinol.* **13**, 572–587
- Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K., and Puigserver, P. (2018) Insulin regulation of gluconeogenesis. *Ann. N. Y. Acad. Sci.* **1411**, 21–35
- Moore, M. C., Coate, K. C., Winnick, J. J., An, Z., and Cherrington, A. D. (2012) Regulation of hepatic glucose uptake and storage *in vivo*. *Adv. Nutr.* **3**, 286–294
- Lucas, P. C., O'Brien, R. M., Mitchell, J. A., Davis, C. M., Imai, E., Forman, B. M., et al. (1991) A retinoic acid response element is part of a pleiotropic domain in the phosphoenolpyruvate carboxykinase gene. *Proc. Natl. Acad. Sci. U. S. A.* **88**, 2184–2188
- Saeed, A., Hoogerland, J. A., Wessel, H., Heegsma, J., Derks, T. G. J., van der Veer, E., et al. (2020) Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels. *Hum. Mol. Genet.* **29**, 264–273
- Rossi, A., Simeoli, C., Salerno, M., Ferrigno, R., Della Casa, R., Colao, A., et al. (2020) Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. *Orphanet J. Rare Dis.* **15**, 99
- Chen, G., Zhang, Y., Lu, D., Li, N.-Q., and Ross, A. C. (2009) Retinoids synergize with insulin to induce hepatic Gck expression. *Biochem. J.* **419**, 645–653

42. Wang, X. L., Herzog, B., Waltner-Law, M., Hall, R. K., Shiota, M., and Granner, D. K. (2004) The synergistic effect of dexamethasone and all-trans-retinoic acid on hepatic phosphoenolpyruvate carboxykinase gene expression involves the coactivator p300. *J. Biol. Chem.* **279**, 34191–34200
43. Greenberg, C. C., Jurczak, M. J., Danos, A. M., and Brady, M. J. (2006) Glycogen branches out: new perspectives on the role of glycogen metabolism in the integration of metabolic pathways. *Am. J. Physiol. Endocrinol. Metab.* **291**, E1–8
44. Saito, H. (2014) Metabolism of iron stores. *Nagoya J. Med. Sci.* **76**, 235–254
45. Quadro, L., Blaner, W. S., Salchow, D. J., Vogel, S., Piantedosi, R., Gouras, P., *et al.* (1999) Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. *EMBO J.* **18**, 4633–4644
46. E, X., Zhang, L., Lu, J., Tso, P., Blaner, W. S., Levin, M. S., *et al.* (2002) Increased neonatal mortality in mice lacking cellular retinol-binding protein II. *J. Biol. Chem.* **277**, 36617–36623
47. Reeves, P. G. (1997) Components of the AIN-93 diets as improvements in the AIN-76A diet. *J. Nutr.* **127**, 838S–841S
48. National Research Council (US) Subcommittee on Laboratory Animal Nutrition (1995) *Nutrient Requirements of Laboratory Animals: Fourth Revised Edition, 1995*, National Academies Press (US), Washington (DC) [online] . (Accessed 12 December 2022)
49. Pellizzon, M. A., and Ricci, M. R. (2020) Choice of laboratory rodent diet may confound data interpretation and reproducibility. *Curr. Dev. Nutr.* **4**, nzaa031
50. Njar, V. C. O., Gediya, L., Purushottamachar, P., Chopra, P., Vasaitis, T. S., Khandelwal, A., *et al.* (2006) Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. *Bioorg. Med. Chem.* **14**, 4323–4340
51. Nelson, C. H., Buttrick, B. R., and Isoherranen, N. (2013) Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics. *Curr. Top Med. Chem.* **13**, 1402–1428
52. Napoli, J. L., and Yoo, H. S. (2020) Retinoid metabolism and functions mediated by retinoid binding-proteins. *Met. Enzymol.* **637**, 55–75